drugset / Trial / NCT04521868

A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients

NCT04521868

Phase 2 Completed 125 enrolled Central South University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia. This study will compare the sulforaphane with placebo. There is a thirty percent change (less than half) of receiving the placebo. The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.

Timeline

Start
2020-08-31
Primary completion
2022-08-12
Completion
2022-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulforaphane Small molecule 1700 mg

Indications